These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25845315)

  • 1. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs.
    Hartung N; Borghardt JM
    PLoS Comput Biol; 2020 Dec; 16(12):e1008466. PubMed ID: 33320846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs.
    Radivojev S; Zellnitz S; Paudel A; Fröhlich E
    Int J Pharm; 2019 Feb; 556():45-56. PubMed ID: 30529665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
    Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
    Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Partial Differential Equation Approach to Inhalation Physiologically Based Pharmacokinetic Modeling.
    Boger E; Wigström O
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):638-646. PubMed ID: 30084547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods.
    Himstedt A; Borghardt JM; Wicha SG
    J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):135-149. PubMed ID: 34585333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.
    Rebello J; Brashier B; Shukla S
    Daru; 2022 Jun; 30(1):229-243. PubMed ID: 35094370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery.
    Wang W; Ouyang D
    Drug Discov Today; 2022 Aug; 27(8):2100-2120. PubMed ID: 35452792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.
    Miller NA; Graves RH; Edwards CD; Amour A; Taylor E; Robb O; O'Brien B; Patel A; Harrell AW; Hessel EM
    Clin Pharmacokinet; 2022 Feb; 61(2):281-293. PubMed ID: 34458976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
    Jones HM; Gardner IB; Collard WT; Stanley PJ; Oxley P; Hosea NA; Plowchalk D; Gernhardt S; Lin J; Dickins M; Rahavendran SR; Jones BC; Watson KJ; Pertinez H; Kumar V; Cole S
    Clin Pharmacokinet; 2011 May; 50(5):331-47. PubMed ID: 21456633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.